Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xellia Pharmaceuticals has acquired manufacturing facilities in Bedford, Ohio, US from a subsidiary of Hikma Pharmaceuticals.
Subscribe to our email newsletter
The acquisition includes parts of the site featuring various new manufacturing units for sterile injectables that are not currently operational.
Hikma will retain the remaining plants including the quality and development center which has been operated by its subsidiary West-Ward Injectables since it bought the site last year.
Xellia plans to hire about 170 new employees across a range of departments at the Bedford site for an initial two-year period.
Xellia Pharmaceuticals CEO Carl-Åke Carlsson said: "The US is a very important market for us, and as a region with a strong manufacturing heritage and a uniquely skilled and specialized workforce, Bedford, Ohio is an ideal location to expand our manufacturing capabilities.
"We are looking forward to being co-located at the Bedford site with Hikma and to continue to work closely with them in the future."
The facilities were earlier owned by Ben Venue Laboratories. Last year, Hikma acquired the Ben Venue assets from Boehringer Ingelheim, following its deal to buy the assets of Bedford Laboratories.
Since its acquisition, Hikma transferred several machines, including lyophlisers and filling lines, to its manufacturing plants in Portugal, Germany and the US.